BACKGROUND: Small cell lung cancer (SCLC) is an aggressive and invasive variant of lung tumors. SCLC, especially in advanced stages, is distinguished by extremely high numbers of circulating tumor cells (CTCs) in comparison to other malignancies. CTCs are operative in tumor spread and are currently enumerated to assess prognosis and response to cytotoxic therapy. Chemosensitivity of SCLC CTCs compared to primary tumors and metastases is not known. METHODS: Establishment of two SCLC CTC cell lines, namely BHGc7 and BHGc10, allowed the in vitro characterization of their chemosensitivity to the second-line chemotherapeutics topotecan and epirubicin in comparison to a range of SCLC cell lines. RESULTS: The SCLC CTC cell lines exhibited an approximately 7- and 12-fold increased chemosensitivity to epirubicin compared to topotecan, respectively, in in vitro cytotoxicity assays. In comparison to a panel of six SCLC cell lines, the two CTC lines showed a significantly higher chemosensitivity to epirubicin (range, 3- to 16-fold) and topotecan (range, 2.2- to 14.4-fold), respectively. CONCLUSIONS: CTC cell lines derived from SCLC patients with recurrent disease exhibit high chemosensitivity to epirubicin vs. topotecan and show considerable more cytotoxicity in response to both compounds in comparison to a panel of SCLC cell lines. Thus, a decrease in the number of CTCs in response to second-line chemotherapy in SCLC patients may overestimate the effect on resident SCLC lesions and metastases.
BACKGROUND:Small cell lung cancer (SCLC) is an aggressive and invasive variant of lung tumors. SCLC, especially in advanced stages, is distinguished by extremely high numbers of circulating tumor cells (CTCs) in comparison to other malignancies. CTCs are operative in tumor spread and are currently enumerated to assess prognosis and response to cytotoxic therapy. Chemosensitivity of SCLC CTCs compared to primary tumors and metastases is not known. METHODS: Establishment of two SCLC CTC cell lines, namely BHGc7 and BHGc10, allowed the in vitro characterization of their chemosensitivity to the second-line chemotherapeutics topotecan and epirubicin in comparison to a range of SCLC cell lines. RESULTS: The SCLC CTC cell lines exhibited an approximately 7- and 12-fold increased chemosensitivity to epirubicin compared to topotecan, respectively, in in vitro cytotoxicity assays. In comparison to a panel of six SCLC cell lines, the two CTC lines showed a significantly higher chemosensitivity to epirubicin (range, 3- to 16-fold) and topotecan (range, 2.2- to 14.4-fold), respectively. CONCLUSIONS: CTC cell lines derived from SCLCpatients with recurrent disease exhibit high chemosensitivity to epirubicin vs. topotecan and show considerable more cytotoxicity in response to both compounds in comparison to a panel of SCLC cell lines. Thus, a decrease in the number of CTCs in response to second-line chemotherapy in SCLCpatients may overestimate the effect on resident SCLC lesions and metastases.
Entities:
Keywords:
Small cell lung cancer (SCLC); chemosensitivity; chemotherapy; circulating tumor cells (CTCs); epirubicin; topotecan
Authors: Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: Chao H Huang; Jo A Wick; Gurusingham Sitta Sittampalam; Victor Sanjit Nirmalanandhan; Apar Kishor Ganti; Prakash C Neupane; Stephen K Williamson; Andrew K Godwin; Sarah Schmitt; Nora J Smart; Sarah Spencer; Peter J Van Veldhuizen Journal: Front Oncol Date: 2014-10-14 Impact factor: 6.244
Authors: Gerhard Hamilton; Maximilian Hochmair; Barbara Rath; Lukas Klameth; Robert Zeillinger Journal: Cell Adh Migr Date: 2016-02-26 Impact factor: 3.405
Authors: Lukas Klameth; Barbara Rath; Maximilian Hochmaier; Doris Moser; Marlene Redl; Felicitas Mungenast; Katharina Gelles; Ernst Ulsperger; Robert Zeillinger; Gerhard Hamilton Journal: Sci Rep Date: 2017-07-13 Impact factor: 4.379
Authors: Gianluigi De Renzi; Giulia De Marco; Michela De Meo; Eleonora Del Rosso; Paola Gazzaniga; Chiara Nicolazzo Journal: Cancer Drug Resist Date: 2022-03-16